drugset / Trial / NCT00160199

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

NCT00160199

Phase 4 Completed 240 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea

Timeline

Start
2004-11
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 300 mg Oral
Subject Progesterone Other / unclassified 400 mg Oral

Indications